135 related articles for article (PubMed ID: 38466015)
1. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.
Zekeridou A; Majed M; Heliopoulos I; Lennon VA
Thorac Cancer; 2019 Apr; 10(4):1001-1004. PubMed ID: 30810271
[TBL] [Abstract][Full Text] [Related]
3. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
[TBL] [Abstract][Full Text] [Related]
5. Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma.
Zekeridou A; McKeon A; Lennon VA
JAMA Neurol; 2016 Jul; 73(7):853-9. PubMed ID: 27135398
[TBL] [Abstract][Full Text] [Related]
6. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.
Fang B; McKeon A; Hinson SR; Kryzer TJ; Pittock SJ; Aksamit AJ; Lennon VA
JAMA Neurol; 2016 Nov; 73(11):1297-1307. PubMed ID: 27618707
[TBL] [Abstract][Full Text] [Related]
8. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments.
McKeon A; Lennon VA; Lachance DH; Fealey RD; Pittock SJ
Arch Neurol; 2009 Jun; 66(6):735-41. PubMed ID: 19506133
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic neuronal intermediate filament autoimmunity.
Basal E; Zalewski N; Kryzer TJ; Hinson SR; Guo Y; Dubey D; Benarroch EE; Lucchinetti CF; Pittock SJ; Lennon VA; McKeon A
Neurology; 2018 Oct; 91(18):e1677-e1689. PubMed ID: 30282771
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Immune-Mediated Paraneoplastic Syndromes to Neurological Manifestations of Neuroendocrine Tumours: A Retrospective Study.
Tannoury J; de Mestier L; Hentic O; Ruszniewski P; Créange A; Sobhani I
Neuroendocrinology; 2021; 111(1-2):123-128. PubMed ID: 32040952
[TBL] [Abstract][Full Text] [Related]
11. Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis.
Popkirov S; Ayzenberg I; Hahn S; Bauer J; Denno Y; Rieckhoff N; Radzimski C; Hans VH; Berg S; Roghmann F; Noldus J; Bien CG; Skodda S; Wellmer J; Stöcker W; Krogias C; Gold R; Schlegel U; Probst C; Komorowski L; Miske R; Kleiter I
Acta Neuropathol Commun; 2017 May; 5(1):40. PubMed ID: 28554330
[TBL] [Abstract][Full Text] [Related]
12. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
13. Presence of paraneoplastic antibodies in non-carcinomatous patients with neurological involvements of unknown cause.
Yanagihashi M; Kawabe K; Ikeda K
J Neurol Sci; 2013 Dec; 335(1-2):197-200. PubMed ID: 24094858
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
15. Aquaporin-4 autoantibodies in a paraneoplastic context.
Pittock SJ; Lennon VA
Arch Neurol; 2008 May; 65(5):629-32. PubMed ID: 18474738
[TBL] [Abstract][Full Text] [Related]
16. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
[TBL] [Abstract][Full Text] [Related]
17. Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery.
Segal Y; Zekeridou A
Curr Opin Neurol; 2024 Jun; 37(3):295-304. PubMed ID: 38533672
[TBL] [Abstract][Full Text] [Related]
18. P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments.
Zalewski NL; Lennon VA; Lachance DH; Klein CJ; Pittock SJ; Mckeon A
Muscle Nerve; 2016 Aug; 54(2):220-7. PubMed ID: 26789908
[TBL] [Abstract][Full Text] [Related]
19. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody.
Thieben MJ; Lennon VA; Boeve BF; Aksamit AJ; Keegan M; Vernino S
Neurology; 2004 Apr; 62(7):1177-82. PubMed ID: 15079019
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
